ReviewPharmaceutics2019
Innovations in Pediatric Drug Formulations and Administration Technologies for Low Resource Settings.
Review in Pharmaceutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Electrospun PLA/PVP K90 Biphasic-Release Sublingual Film for Motion Sickness Treatment.Biomolecules · 2026Article
- Three-Dimensionally Printed Paediatric Medicines: Formulation, Process, and Regulatory Considerations.Pharmaceutics · 2025Review
- Off-label prescribing in Italian pediatric practice: insights from a nationwide survey.European journal of pediatrics · 2025Article
- Prevalence of drug-drug interactions in children with cardiac disorders receiving off-label drugs in a single centre in Pakistan: a cross-sectional study.BMJ paediatrics open · 2025Article
- Choosing the "Ideal" Oral Dosage Form for Pediatric Patients: Parents' Perspectives on Children's Preferences with a Focus on Orodispersible Tablets.Children (Basel, Switzerland) · 2025Article
- Three-Dimensional-Printed Isoniazid Chewable Gels for On-Demand Latent Tuberculosis Treatment in Children.Pharmaceutics · 2025Article
- Antiretroviral medications for pediatric use in the context of the Unified Health System: are there therapeutic gaps in Brazil?Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo · 2025Article
- A Review on Ocular Nanoformulation Based Formulations with Highlights on Pediatric Ocular Pharmacokinetics.Pharmaceutical nanotechnology · 2025Review
- Optimization and prioritization of paediatric drugs for visceral leishmaniasis.Frontiers in pediatrics · 2025Article
- Pediatric Formulations Developed by Extrusion-Based 3D Printing: From Past Discoveries to Future Prospects.Pharmaceutics · 2024Review
- A novel home-based method for preparing suspensions of anti-TB drugs.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2023Article
- Development and evaluation of an assessment of the age-appropriateness/inappropriateness of formulations used in children.International journal of clinical pharmacy · 2022Article
- Health technology assessment of paediatric medicines: European landscape, challenges and opportunities inside the conect4children project.British journal of clinical pharmacology · 2022Review
- Innovative approaches and recent advances in the study of ontogeny of drug metabolism and transport.British journal of clinical pharmacology · 2022Review
- Stability Study of Baclofen in an Oral Powder Form Compounded for Pediatric Patients in Japan.Children (Basel, Switzerland) · 2022Article
- A Design Approach to Optimise Secure Remote Three-Dimensional (3D) Printing: A Proof-of-Concept Study towards Advancement in Telemedicine.Healthcare (Basel, Switzerland) · 2022Article
- Assessing the Appropriateness of Formulations on the WHO Model List of Essential Medicines for Children: Development of a Paediatric Quality Target Product Profile Tool.Pharmaceutics · 2022Article
- Dosage Forms Suitability in Pediatrics: Acceptability of Analgesics and Antipyretics in a German Hospital.Pharmaceutics · 2022Article
- Article
- Stability of clonidine hydrochloride in an oral powder form compounded for pediatric patients in Japan.Journal of pharmaceutical health care and sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite advances in regulations and initiatives to increase pediatric medicine development, there is still an unmet need for age-appropriate medicines for children. The availability of pediatric formulations is particularly lacking in resource poor areas, due to, for example, area-specific disease burden and financial constraints, as well as disconnected supply chains and fragmented healthcare systems. The paucity of authorized pediatric medicines often results in the manipulation and administration of products intended for adults, with an increased risk of mis-dosing and adverse reactions. This article provides an overview of the some of the key difficulties associated with the development of pediatric medicines in both high and low resource areas, and highlights shared and location specific challenges and opportunities. The utilization of dispersible oral dosage forms and suppositories for low and middle-income countries (LMICs) are described in addition to other platform technologies that may in the future offer opportunities for future pediatric medicine development for low resource settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.